ERBB2 and ovarian carcinoma: In this work, we have investigated the use of Ec1-LoPE as the EpCAM-targeting component and the mAb trastuzumab as the HER2-targeting component for combination therapy of mice bearing HER2- and EpCAM-expressing SKOV3 ovarian cancer xenografts.